Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication.
Jackelyn MurrayHarrison C BergeronLes P JonesZachary Beau ReenerDavid E MartinFred D SancilioRalph A TrippPublished in: Viruses (2022)
RNA viruses like SARS-CoV-2, influenza virus, and respiratory syncytial virus (RSV) are dependent on host genes for replication. We investigated if probenecid, an FDA-approved and safe urate-lowering drug that inhibits organic anion transporters (OATs) has prophylactic or therapeutic efficacy to inhibit RSV replication in three epithelial cell lines used in RSV studies, i.e., Vero E6 cells, HEp-2 cells, and in primary normal human bronchoepithelial (NHBE) cells, and in BALB/c mice. The studies showed that nanomolar concentrations of all probenecid regimens prevent RSV strain A and B replication in vitro and RSV strain A in vivo, representing a potential prophylactic and chemotherapeutic for RSV.
Keyphrases
- respiratory syncytial virus
- induced apoptosis
- cell cycle arrest
- sars cov
- respiratory tract
- endoplasmic reticulum stress
- cell death
- signaling pathway
- type diabetes
- oxidative stress
- emergency department
- genome wide
- risk assessment
- cell proliferation
- metabolic syndrome
- adipose tissue
- induced pluripotent stem cells
- drug induced
- human health
- water soluble